← Eichor
Study identifier: NCT06611319 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

ENhanced Recovery and ABbreviated LEngth of Anticoagulation for Thromboprophylaxis After Primary Hip Arthroplasty

Condition: Hip Arthroplasty, Total · Prevention of Venous Thromboembolism  ·  Sponsor: Prof. Stavros Konstantinides, MD

PhasePhase 3
Planned participants2932
Who can joinAll sexes, 18 Years to 85 Years
Healthy volunteersNo

About this study

Surgical hip replacement (total hip arthroplasty, THA) is associated with a high risk of venous thromboembolism, but the appropriate duration of postoperative medical thromboprophylaxis ("anticoagulation") remains highly controversial. The international randomized controlled trial (RCT) "ENhanced recovery and ABbreviated LEngth of Anticoagulation for Thromboprophylaxis after primary Hip Arthroplasty" (ENABLE-Hip) will enroll patients undergoing elective THA that are eligible for early mobilization after surgery. The trial will compare a regimen of short-duration (10-day) postoperative anticoagulation (experimental group) to standard-duration (35-day) postoperative anticoagulation (control group) using the direct oral anticoagulant Rivaroxaban (brand name: Xarelto) at the recommended dose. Thus, ENABLE-Hip will be the first major RCT to directly test an overall reduction in the duration of post-THA thromboprophylaxis instead of replacing one antithrombotic drug or regimen by another. Follow-up visits after hospital discharge will be on day 35 and on day 90 after surgery. The primary outcome is acute symptomatic proximal deep vein thrombosis, or symptomatic or fatal pulmonary embolism, within 90 days after surgery. If ENABLE-Hip will demonstrate 'non-inferiority' of the experimental intervention, its benefits will be obvious, as patients are spared many days of unnecessary (and potentially harmful in terms of bleeding risk) anticoagulation.

This description comes directly from the study's public registry record.

Talk to the study team

Nadine Martin, Dr.  ·  +496131178376  ·  nadine.martin@unimedizin-mainz.de

Susanne Fischer, M.Sc.  ·  +496131178382  ·  susanne.fischer@unimedizin-mainz.de

Always discuss trial participation with your own doctor first.

Locations (6)

Kepler University Medical Center, Orthopedics and TraumatologyLinz, Upper Austria, AustriaRecruiting
Sana Clinics Sommerfeld, Dpt. for Surgical OrthopaedicsKremmen, Brandenburg, GermanyRecruiting
GPR Rüsselsheim Health and Care CenterRüsselsheim am Main, Hesse, GermanyRecruiting
University Medical Center Mainz, Center for Orthopedics and Trauma SurgeryMainz, Rhineland-Palatine, GermanyRecruiting
University Medical Center Dresden, University Center for Orthopaedics, Trauma & Plastic SurgeryDresden, Saxony, GermanyRecruiting
Evangelical Forest Hospital Berlin - Orthopaedics and Trauma SurgeryBerlin, GermanyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06611319